vs
Side-by-side financial comparison of Loar Holdings Inc. (LOAR) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
Loar Holdings Inc. is the larger business by last-quarter revenue ($131.8M vs $75.5M, roughly 1.7× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 19.3%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 19.8%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
LOAR vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $131.8M | $75.5M |
| Net Profit | $12.5M | — |
| Gross Margin | 52.1% | 69.3% |
| Operating Margin | 18.0% | 22.7% |
| Net Margin | 9.5% | — |
| Revenue YoY | 19.3% | 27.7% |
| Net Profit YoY | 239.5% | — |
| EPS (diluted) | $0.13 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $131.8M | $75.5M | ||
| Q3 25 | $126.8M | $54.5M | ||
| Q2 25 | $123.1M | $52.4M | ||
| Q1 25 | $114.7M | $46.0M | ||
| Q4 24 | $110.4M | $59.1M | ||
| Q3 24 | $103.5M | $80.5M | ||
| Q2 24 | $97.0M | $47.1M | ||
| Q1 24 | $91.8M | $43.8M |
| Q4 25 | $12.5M | — | ||
| Q3 25 | $27.6M | $8.8M | ||
| Q2 25 | $16.7M | $5.9M | ||
| Q1 25 | $15.3M | $3.0M | ||
| Q4 24 | $3.7M | — | ||
| Q3 24 | $8.7M | $20.3M | ||
| Q2 24 | $7.6M | $-4.5M | ||
| Q1 24 | $2.2M | $-4.8M |
| Q4 25 | 52.1% | 69.3% | ||
| Q3 25 | 52.7% | 77.7% | ||
| Q2 25 | 53.8% | 76.5% | ||
| Q1 25 | 52.1% | 77.1% | ||
| Q4 24 | 48.9% | 76.4% | ||
| Q3 24 | 51.1% | 63.9% | ||
| Q2 24 | 49.0% | 77.4% | ||
| Q1 24 | 48.4% | 75.5% |
| Q4 25 | 18.0% | 22.7% | ||
| Q3 25 | 22.9% | 17.6% | ||
| Q2 25 | 22.2% | 12.7% | ||
| Q1 25 | 22.8% | 8.7% | ||
| Q4 24 | 19.2% | 22.6% | ||
| Q3 24 | 22.1% | 27.4% | ||
| Q2 24 | 22.9% | -4.6% | ||
| Q1 24 | 23.3% | -5.3% |
| Q4 25 | 9.5% | — | ||
| Q3 25 | 21.8% | 16.2% | ||
| Q2 25 | 13.6% | 11.2% | ||
| Q1 25 | 13.4% | 6.5% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 8.4% | 25.2% | ||
| Q2 24 | 7.9% | -9.6% | ||
| Q1 24 | 2.4% | -11.0% |
| Q4 25 | $0.13 | $0.26 | ||
| Q3 25 | $0.29 | $0.17 | ||
| Q2 25 | $0.17 | $0.12 | ||
| Q1 25 | $0.16 | $0.06 | ||
| Q4 24 | $-11023.48 | $0.40 | ||
| Q3 24 | $0.09 | $0.41 | ||
| Q2 24 | $0.09 | $-0.09 | ||
| Q1 24 | $11023.54 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.8M | $97.5M |
| Total DebtLower is stronger | $715.7M | $22.7M |
| Stockholders' EquityBook value | $1.2B | $130.3M |
| Total Assets | $2.0B | $216.3M |
| Debt / EquityLower = less leverage | 0.61× | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.8M | $97.5M | ||
| Q3 25 | $99.0M | $94.4M | ||
| Q2 25 | $103.3M | $96.0M | ||
| Q1 25 | $80.5M | $93.2M | ||
| Q4 24 | $54.1M | $101.0M | ||
| Q3 24 | $55.2M | $96.7M | ||
| Q2 24 | $73.2M | $96.8M | ||
| Q1 24 | $28.2M | $107.2M |
| Q4 25 | $715.7M | $22.7M | ||
| Q3 25 | $279.4M | $34.0M | ||
| Q2 25 | $277.7M | $45.3M | ||
| Q1 25 | $277.5M | $56.7M | ||
| Q4 24 | $277.3M | $68.0M | ||
| Q3 24 | $602.1M | $79.3M | ||
| Q2 24 | $250.7M | $90.7M | ||
| Q1 24 | $534.2M | $102.0M |
| Q4 25 | $1.2B | $130.3M | ||
| Q3 25 | $1.2B | $115.3M | ||
| Q2 25 | $1.1B | $104.7M | ||
| Q1 25 | $1.1B | $97.1M | ||
| Q4 24 | $1.1B | $92.1M | ||
| Q3 24 | $769.8M | $71.1M | ||
| Q2 24 | $758.4M | $48.5M | ||
| Q1 24 | $420.6M | $51.0M |
| Q4 25 | $2.0B | $216.3M | ||
| Q3 25 | $1.5B | $202.9M | ||
| Q2 25 | $1.5B | $194.9M | ||
| Q1 25 | $1.5B | $196.2M | ||
| Q4 24 | $1.5B | $213.3M | ||
| Q3 24 | $1.5B | $220.7M | ||
| Q2 24 | $1.1B | $205.0M | ||
| Q1 24 | $1.1B | $214.1M |
| Q4 25 | 0.61× | 0.17× | ||
| Q3 25 | 0.24× | 0.30× | ||
| Q2 25 | 0.25× | 0.43× | ||
| Q1 25 | 0.25× | 0.58× | ||
| Q4 24 | 0.25× | 0.74× | ||
| Q3 24 | 0.78× | 1.12× | ||
| Q2 24 | 0.33× | 1.87× | ||
| Q1 24 | 1.27× | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 2.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $14.4M | ||
| Q3 25 | $29.7M | $9.7M | ||
| Q2 25 | $23.8M | $14.1M | ||
| Q1 25 | $28.4M | $3.6M | ||
| Q4 24 | $20.7M | $15.6M | ||
| Q3 24 | $16.3M | $11.0M | ||
| Q2 24 | $7.1M | $1.0M | ||
| Q1 24 | $10.8M | $11.2M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | 2.43× | — | ||
| Q3 25 | 1.08× | 1.10× | ||
| Q2 25 | 1.42× | 2.41× | ||
| Q1 25 | 1.85× | 1.21× | ||
| Q4 24 | 5.62× | — | ||
| Q3 24 | 1.89× | 0.54× | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 4.81× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
PBYI
Segment breakdown not available.
